| 06.08 23:11 | Amgen schweigt zu Maritide - Gemischte Zahlen und Ausblick drücken Kurs |
| 06.08 23:11 | dpa-AFX: Amgen schweigt zu Maritide - Gemischte Zahlen und Ausblick drücken Kurs |
| 06.08 23:06 | dpa-AFX: Amgen schweigt zu Maritide - Gemischte Zahlen und Ausblick drücken Kurs |
| 06.08 22:07 | dpa-AFX: *AMGEN NACHBÖRSLICH -2,4% - GEMISCHTE QUARTALSZAHLEN |
| 06.08 22:04 | dpa-AFX: Amgen Inc. Q2 Profit Decreases, But Beats Estimates |
| 06.08 22:03 | dpa-AFX: *AMGEN Q2 REVENUES $8.39 BLN VS. $6.99 BLN LAST YEAR |
| 06.08 22:03 | dpa-AFX: *AMGEN Q2 EPS $1.38 VS. $2.57 YEAR AGO |
| 06.08 22:03 | dpa-AFX: *AMGEN Q2 NET INCOME $746 MLN VS. $1.38 BLN PRIOR YEAR |
| 06.08 12:00 | dpa-AFX: Amgen Q2 24 Earnings Conference Call At 4:30 PM ET |
| 02.08 22:34 | dpa-AFX: *AMGEN DECLARES QUARTERLY DIVIDEND OF $2.25/SHARE, PAYABLE SEPT. 6/ RECORD AUG. 16 |
| 02.08 22:05 | dpa-AFX: *AMGEN INC. (AMGN) DECLARES $ 2.25 DIVIDEND FOR Q3 24, RECORD DATE 8/16/2024 |
| 05.06 15:50 | dpa-AFX: Amgen Reports Positive Results For Phase 3 Trial Of Uplizna For IgG4-RD |
| 05.06 15:06 | dpa-AFX: *AMGEN'S UPLIZNA SHOWS PROMISE IN PHASE 3 TRIAL FOR IMMUNOGLOBULIN G4-RELATED DISEASE |
| 30.05 11:56 | dpa-AFX: Biotech Stocks Facing FDA Decision In June 2024 |
| 30.05 11:21 | dpa-AFX: Amgen's Bkemv Approved As First Interchangeable Biosimilar To Soliris |
| 22.05 07:32 | dpa-AFX: Roche: FDA Grants Breakthrough Device Designation For Bood Test Measuring Lp(a) |
| 22.05 07:25 | dpa-AFX: Roche erhält von FDA 'Breakthrough Device Designation' für Bluttest |
| 20.05 03:38 | dpa-AFX: AstraZeneca: New Data Shows Tezspire's Role In Future COPD Treatment |
| 17.05 03:01 | dpa-AFX: Amgen: FDA Approves Imdelltra For Extensive-Stage Small Cell Lung Cancer Treatment |
| 15.05 10:48 | dpa-AFX: *LBBW HEBT ZIEL FÜR AMGEN AUF 310 (290) USD - 'HALTEN' |
|
|
